AbbVie is expanding its immunology and inflammation portfolio by acquiring Capstan Therapeutics for up to $2.1 billion. Capstan, a startup developing in vivo CAR-T therapies for autoimmune diseases, fibrosis, and cancer, has a phase 1 program targeting B cell-mediated disorders. This acquisition adds novel in vivo immune engineering technology to AbbVie’s pipeline and signals their commitment to next-generation cell therapies. Multiple articles cover the deal and its strategic implications.